Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma: A Multicenter, Open-label, Randomized, Phase III Clinical Study

NCT07371611 is registered in ClinicalTrials.gov with Qunxing Li,MD as lead sponsor.

NCT NCT07371611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma: A Multicenter, Open-label, Randomized, Phase III Clinical Study
Lead sponsor
Qunxing Li,MD
Phase
Phase 3
Overall status
Recruiting
Start date
January 1, 2026
Completion date
December 31, 2033
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced oral squamous cell carcinoma, oral squamous cell carcinoma (oscc)